Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M

Xeris Biopharma Holdings, Inc.

2025-Q3 EPS reported -$0.07 revenue$206,038,000

Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).
Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).
Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.
FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.
CEO cites record quarter driven by increased patient demand across all three products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.